跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2023/11/060212
CTRI/2023/11/060212招募中2 期

A Phase 2a, Multi-center, Open Label, Dose Optimization, Pilot Study to Assess the Safety and Tolerability at the Maximum Tolerated Dose of Parenteral TK-112690 in Non-Metastatic Squamous Cell Carcinoma of Head and Neck Patients Scheduled to Receive Chemoradiation. - NI

Tosk Inc0 个研究点目标入组 0 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
2 期
状态
招募中
发起方
Tosk Inc
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •1. Patient must sign study-specific Informed consent prior to study entry.
  • •2. Male or Female patients aged 18 – 75 years.
  • •3. Pathologically (histologically or cytologically) proven (from primary lesion and/or lymph nodes) diagnosis of squamous cell carcinoma of the oral cavity (Refer Definition in 10.13.1), oropharynx or hypopharynx.
  • •4. Patients must have at least 1 mucosal site of the oral cavity/oropharynx/hypopharnyx mucosa assessable by visual transoral inspection that will receive cumulative radiation dose of 60-70 Gy.
  • •Note: Unavoidable doses of at least 60 Gy, to include entrance, exit, and scatter doses, still constitutes planned radiation.
  • •5. Patients with tumors of the larynx or hypopharynx are eligible only if it is anticipated that at least 1 index site in the oral cavity/oropharynx/hypopharnyx mucosa (Refer section 10.13.1) will receive cumulative radiation dose of 60-70 Gy.
  • •6. Patients with Stage I to III or IVA-B as per AJCC, Cancer Imaging Manual, 8th edition, at study entry, including no distant metastases other than non- metastatic SCCHN, based upon the following minimum diagnostic workup:
  • •- History/physical examination, including documentation of tobacco/alcohol use and current medications (including opioids/dosing), within 8 weeks prior to enrollment.
  • •- PET /CT Scan/MRI within 8 weeks of enrollment.
  • •7. Mucositis Grade = 1 per WHO Scale and Xerostomia of Grade = 2 per CTCAE version 5.0.
  • •8. ECOG Performance Status = 2.
  • •9. Adequate bone marrow function as per CTCAE V 5, defined as follows (within 2 weeks prior to enrollment):
  • •- Absolute neutrophil count = 1500 cells/mm3 based upon CBC/differential obtained within 2 weeks prior to enrollment.
  • •- Platelets = 100,000 cells/mm3 based upon CBC obtained within 2 weeks prior to enrollment.
  • •- Hemoglobin = 8.0 g/dl based upon CBC obtained within 2 weeks prior to randomization (Note: The use of transfusion or other intervention to achieve Hgb > 8.0 g/dl is acceptable).
  • •10. Adequate hepatic function with bilirubin = 1.5 x upper-normal limit (ULN), AST or ALT
  • •=3 x ULN within 2 weeks prior to enrollment.
  • •11. Adequate renal function with serum creatinine < 1.5 mg/dl and creatinine clearance (CrC) = 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula. CrC male equals [(140 - age) x (wt in kg)] / [(Serum Cr mg/dl) x (72)]. CrC female equals 0.85 x (CrCl male) within 2 weeks prior to enrollment.
  • •12. Negative serum pregnancy test for women of childbearing potential.
  • •13. Women of childbearing potential and male participants with female partners of childbearing potential must practice adequate contraception.

排除标准

  • •1. Stage IVC (Any T, Any N, M1) per AJCC Cancer Staging Manual. 8th ed, or distant metastases at protocol study entry.
  • •2. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years.
  • •3. Patients who have not fully recovered after prior to SCCHN surgery. (Except those Patients who have had prior surgery and have fully recovered and patients who may have surgery in the future are eligible).
  • •4. Severe, active co-morbidity, defined as follows:
  • •-Symptomatic and/or uncontrolled cardiac disease, New York Heart Association Classification III or IV.
  • •-Transmural myocardial infarction within the last 6 months.
  • •-Acute bacterial or fungal infection requiring intravenous antibiotics at the time of screening.
  • •-Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of screening.
  • •-Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.
  • •-Patients known to be sero-positive for human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV).
  • •5. Concurrent available or experimental systemic or topical pharmaceuticals or devices or low-level laser therapy for OM. Oral rinses—limited to sodium bicarbonate, lidocaine, and antifungal agents—will be permitted. Supportive care per ASCO guidelines is permitted and encouraged.
  • •6. Collagen vascular disease, such as scleroderma.
  • •7. Previous treatment with palifermin or other keratinocyte growth factors, such as velafermin or repifermin, within a month of enrollment.
  • •8. Any prohibited therapy 2 weeks prior to enrollment. (see Section 8.4)
  • •9. Pregnancy, breast feeding or women of childbearing potential and men who a sexually active and not willing/able to use medically acceptable forms of contraception.
  • •10. Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results.
  • •11. Known hypersensitivity study medication or excipients in the formulation.
  • •12. Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his/her compliance in the study.
  • •13. The use of steroids during treatment.
  • •14. Supportive care is allowed after approval of medical monitoring

研究者

发起方
Tosk Inc

相似试验

进行中（未招募）
1 期
Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancerHER2 positive or HER2-low metastatic breast cancerMedDRA version: 20.1Level: PTClassification code: 10055113Term: Breast cancer metastatic Class: 100000004864MedDRA version: 23.0Level: PTClassification code: 10065430Term: HER2 positive breast cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104
CTIS2023-506866-30-00Eisai Limited135
进行中（未招募）
不适用
A trial to see the effects of increased doses of ACP-196 (the test drug) in subjects with Leukemia or special types of LeukemiaChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome or Prolymphocytic LeukemiaMedDRA version: 18.0Level: LLTClassification code 10073483Term: B-cell prolymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: LLTClassification code 10003910Term: B-cell small lymphocytic lymphoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10058728Term: Richter's syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-000440-15-DEAcerta Pharma BV240
进行中（未招募）
1 期
A trial to see the effects of increased doses of ACP-196 (the test drug) in subjects with Leukemia
EUCTR2014-000440-15-GBAcerta Pharma, BV286
招募中
2 期
A trial to see the effects of increased doses of ACP-196 (the test drug) in subjects with LeukemiaProlymphocytic LeukemiaChronic Lymphocytic Leukemia
2023-509346-35-00Acerta Pharma B.V.1
进行中（未招募）
不适用
Study of WNT974 in combination with LGX818 and cetuximab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) and Wnt pathway mutationsMedDRA version: 19.0Level: HLTClassification code 10010023Term: Colorectal neoplasms malignantSystem Organ Class: 100000004864colorectal cancer
EUCTR2014-002826-11-FRArray BioPharma Inc.55